

Catecholamine synthesizing enzymes in 70 cases of functioning and non-functioning pheochromocytoma and extra-adrenal paraganglioma

Noriko Kimura¹, Yukio Miura², Ikuko Nagatsu³, and Hiroshi Nagura¹

Departments of ¹ Pathology and ² Internal Medicine, Tohoku University School of Medicine, Sendai, Japan

³ Department of Anatomy, Fujita Health University, Toyoake, Japan

Received November 12, 1991 / Received after revision February 3, 1992 / Accepted February 4, 1992

Summary. Immunohistochemical localization of the catecholamine synthesizing enzymes, tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), dopamine- β -hydroxylase (DBH) and phenylethanolamine N-methyltransferase (PNMT), was investigated in 70 cases of functioning and non-functioning pheochromocytomas comprising 52 of adrenal and 18 of extra-adrenal origin. Of 59 functioning tumours, 30 were mixed epinephrine and norepinephrine-producing (mixed type) and 29 were norepinephrine-producing tumours. TH, AADC and DBH were detected in all functioning pheochromocytomas, but PNMT was limited to the mixed-type pheochromocytomas. Non-functioning pheochromocytomas were divided into two groups, comprising a complete type, which induced neither elevated plasma catecholamines nor their metabolites in urine, and an incomplete type which exhibited no elevated plasma catecholamines, but showed a slightly high urinary vanillylmandelic acid level. In the non-functioning complete-type tumours, immunoreactive TH was negative, but the incomplete tumours of the adrenal medulla had all four enzymes, and corresponded to a mixed-type pheochromocytoma. AADC and DBH were present universally in all functioning and non-functioning tumours, including TH-negative tumours. TH is a rate-limiting enzyme of catecholamine biosynthesis and deficiency of TH is an important feature of extra-adrenal non-functioning pheochromocytomas.

Key words: Pheochromocytoma – Tyrosine hydroxylase – Aromatic L-amino acid decarboxylase – Dopamine β -hydroxylase – Phenylethanolamine N-methyltransferase

Introduction

Pheochromocytoma is derived from the paraganglia and usually produces catecholamines; clinical symptoms

depend on the plasma levels of the catecholamines produced by the tumour. Our previous study revealed that plasma catecholamine levels are directly correlated to the catecholamine content of the tumours (Kimura et al. 1984). When a patient with pheochromocytoma has neither clinical symptoms nor elevated serum or urinary catecholamine levels, that tumour is described as non-functioning. Non-functioning pheochromocytomas have similar histology to those of the functioning type and although the size of the neuroendocrine granules is, by comparison, smaller and the number of granules is somewhat less than those of the functioning pheochromocytoma, no essential differences have been found between the histopathology.

Tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase (AADC), dopamine- β -hydroxylase (DBH) and phenylethanolamine-N-methyltransferase (PNMT) are the enzymes needed to synthesize catecholamines for dopa, dopamine, norepinephrine and epinephrine respectively (Verhofstad et al. 1983). TH is the rate-limiting enzyme in the synthesis of catecholamines in neural tissues and the adrenal medulla (Han et al. 1987). If both DBH and PNMT reactions are positive, then it can be concluded that the cells synthesize epinephrine. Alternatively, if the cells are immunoreactive only to DBH and negative for PNMT, it can be deduced that they synthesize norepinephrine (Verhofstad et al. 1983). We performed an immunohistochemical study of those enzymes on functioning and non-functioning pheochromocytomas and extra-adrenal paragangliomas to clarify whether there is a close correlation between immunoreactive expression of catecholamine-synthesizing enzymes and tumour types classified by plasma and/or urinary catecholamine levels, such as mixed epinephrine and norepinephrine-producing tumours and norepinephrine-producing tumours, and also to determine if there is an abnormality in the process of catecholamine synthesis in non-functioning tumours.

Materials and methods

Seventy cases of pheochromocytoma were examined. Multiple catecholamine measurements of blood and urine were performed

Correspondence to: N. Kimura, Department of Pathology, Tohoku University School of Medicine, 1–2 Seiryomachi Aoba-ku, Sendai 980 Japan

pre-operatively in all except 7 cases. Surgically operated tumours were divided into three groups: functioning, non-functioning and unknown types, on the basis of catecholamine levels in the plasma and/or urine. The location of the tumours is summarized in Table 1.

There were 59 functioning tumours, including 30 of the mixed epinephrine and norepinephrine-producing type (mixed type) and 29 of the norepinephrine-producing type.

In the non-functioning type, there were 3 tumours of adrenal origin and 1 from the urinary bladder. These non-functioning adrenal pheochromocytomas had a normal plasma level of catecholamines, but an increased pre-operative urinary vanillylmandelic acid (VMA). Intra-operative palpation of the tumour induced high blood pressure and arrhythmia. These tumours were called non-functioning incomplete pheochromocytomas in the present study.

In a case of malignant pheochromocytoma of the urinary bladder with multiple metastasis in the lymph nodes, pelvis and mediastinum, the levels of both serum catecholamines and urinary VMA were always within the normal range; epinephrine: 16 pg/ml (normal <100 pg/ml); norepinephrine: 60 pg/ml (normal <300 pg/ml); VMA 2.0 mg/day (normal <5 mg/day) in spite of frequent measurements. This type of tumour was called non-functioning complete pheochromocytoma. Thus we divided non-functioning pheochromocytomas into two groups: complete and incomplete, the former tumour without evidence of excessive catecholamine production determined by analysis of serum catecholamine and urinary VMA and the latter with a normal range of serum catecholamine levels, but a slight increase in urinary VMA. Although 1 patient did not complain of clinical symptoms associated with hypercatecholaminaemia, stimulation (intra-operative palpation) induced catecholamine release into the blood as well as hypertension and tachycardia. This case was included among those classed as incomplete. There were 3 cases of incomplete, and 1 case of complete tumour in the present study.

Seven cases, including 3 carotid body tumours, 1 spinal cord paraganglioma, 1 urinary bladder paraganglioma and 2 adrenal pheochromocytomas, were operated on without pre-operative catecholamine analysis. They had no symptoms of hypercatecholaminaemia at the time of operation.

Four malignant cases with multiple distant metastases, including 3 norepinephrine-producing pheochromocytomas and 1 non-functioning pheochromocytoma, were examined.

Tumour tissue was fixed immediately in 10% buffered formalin and embedded in paraffin. For immunohistochemical procedures, the streptavidin-biotin-peroxidase complex method was employed using a Histofine SAB-PO kit (Nichirei, Tokyo) as described elsewhere (Kimura et al. 1988, 1990). The source and working dilution of the primary antibodies were as follows. TH for rat pheochromocytoma (Chemicon, El Segundo, Calif., 1:200), AADC for bovine adrenal medulla (Dr. I. Nagatsu, Toyoake, 1:1000), DBH for bovine adrenal medulla (Dr. I. Nagatsu, Toyoake, 1:50), PNMT for bovine adrenal medulla (Bioclone, Marrickville NSW, Australia, 1:2000). All of these antibodies were raised in rabbits. The specificity of the antibodies for AADC and DBH has been described elsewhere (Nagatsu et al. 1988). Primary antibodies were incubated at 4°C for 18 h. Indicative reaction for peroxidase was performed using 0.03% 3,3-diaminobenzidine 4 hydrochloride. Sections were counterstained with methyl green.

For negative controls, normal rabbit serum diluted 1:300 was used. For the positive controls, human adrenal medulla was used.

Results

All the enzymes TH, AADC, DBH and PNMT were detected in the normal adrenal medulla of the positive controls. Immunoreactive TH and AADC were diffusely demonstrated in the cytoplasm of almost all medullary cells. In contrast, immunoreactive DBH was shown as rough granules located mainly in the periphery of the cytoplasm. PNMT was shown diffusely in the cytoplasm. Cells immunoreactive to PNMT tended to be located in the sub-cortical region. Negative controls did not exhibit immunoreactivity.

Table 1. Immunohistochemical localization of catecholamine-synthesizing enzymes in pheochromocytomas and paragangliomas

	Cases examined	Cases positive for			
		TH	AADC	DBH	PNMT
I. Functioning	59				
1) Mixed epinephrine and norepinephrine-producing type	30				
a) Adrenal gland	29	29	29	29	29
b) Retroperitoneum	1	1	1	1	1
2) Norepinephrine-producing type	29				
a) Adrenal gland	18	18	18	18	0
b) Extra-adrenal gland	11	11	11	11	0
II. Non-functioning	4				
1) Incomplete, adrenal gland	3	3	3	3	3
2) Complete, urinary bladder	1	0	1	1	0
III. Unknown	7				
Carotid body	3	1	3	3	0
Spinal cord	1	0	1	1	0
Urinary bladder	1	1	1	1	0
Adrenal gland	2	2	2	2	2
Total	70	66	70	70	35

TH, tyrosine hydroxylase; AADC, Aromatic L-amino acid decarboxylase; DBH, dopamine-β-hydroxylase; PNMT, phenylethanolamine N-methyltransferase




Fig. 1. Although there is some heterogeneity in immunoreactivity, almost all tumour cells are immunoreactive to tyrosine hydroxylase (TH) in a functioning adrenal pheochromocytoma. $\times 400$. (Case: 49-year-old female; plasma epinephrine: 890 pg/ml; plasma norepinephrine: 5800 pg/ml; tumour size: 65 \times 55 \times 55 mm, 112 g)




Fig. 2. All tumour cells are strongly immunoreactive to aromatic L-amino acid decarboxylase (AADC) in a functioning adrenal pheochromocytoma. $\times 200$. (Case: 41-year-old female; plasma epinephrine: 1900 pg/ml; plasma norepinephrine: 2080 pg/ml; tumour size: 57 \times 46 \times 38 mm, 60 g)

In the functioning pheochromocytomas, almost all tumour cells were diffusely stained with TH (Fig. 1) and AADC (Fig. 2). Immunoreactive DBH was observed in all tumours, but there were fewer cells immunoreactive to DBH (Fig. 3) than to TH and AADC. PNMT immunoreactivity was limited to the mixed tumours (Fig. 4), and no norepinephrine-producing type had cells immunoreactive to PNMT (Fig. 5).

There was no histological difference between functioning and non-functioning tumour tissue stained with haematoxylin and eosin (Fig. 6).

In the non-functioning pheochromocytomas, TH immunoreactivity was observed in 3 of 4 tumours. All positive tumours were of the incomplete type. Only the

tumour of complete type in the urinary bladder was TH negative (Fig. 7). AADC immunoreactivity was strongly demonstrated in all non-functioning tumours including the TH-negative, complete type (Fig. 8). Cells immunoreactive to DBH were observed in all 4 tumours; however the number of DBH-positive cells was much less than that of functioning pheochromocytomas (Fig. 9). Immunoreactive PNMT was observed in all 3 adrenal tumours, but not in a complete-type tumour of the urinary bladder.

In the unknown group, adrenal pheochromocytomas were immunoreactive to all four enzymes, corresponding to mixed pheochromocytoma. Extra-adrenal tumours located in the carotid body, spinal cord and




Fig. 3. Dopamine- β -hydroxylase (DBH) immunoreactivity is sporadically but strongly observed in a functioning adrenal pheochromocytoma ($\times 400$). (Same case as Fig. 1)




Fig. 4. Phenylethanolamine-*N*-methyltransferase (PNMT) immunoreactivity is limited in an mixed type epinephrine and norepinephrine producing adrenal pheochromocytoma. $\times 400$. (Case: 61-year-old female; plasma epinephrine: 1860 pg/ml; plasma norepinephrine: 2192 pg/ml; tumour size: 42 \times 33 \times 35 mm, 23 g)

urinary bladder showed strong immunoreactivity to AADC, but TH was detected in only 1 of 3 carotid body tumours and a urinary bladder tumour. Two carotid body tumours and a spinal cord tumour were negative for TH. These TH-negative tumours were larger than the positive ones, with a maximum diameter of 3.0 cm versus 0.5 cm. DBH was sporadically positive in all 5, but PNMT was negative in all cases.

In 4 malignant tumours with multiple distant metastases, a tumour of the urinary bladder, non-functioning, complete type, had no cells immunoreactive to TH, but cells immunoreactive to AADC and DBH were observed. The other 3 tumours, which were of the norepinephrine-producing type, were immunoreactive to TH,

AADC and DBH. The results are summarized in Table 1.

Discussion

Since the report of Goldstein et al. (1971), there have been many investigations of catecholamine-synthesizing enzymes in the adrenal medulla (Eränkö et al. 1966; Wurtman and Axelrod 1966; Nagatsu and Kondo 1974; Verhofstad et al. 1979), the extra-adrenal paraganglion system (Eränkä et al. 1966), and brain (Nagatsu et al. 1988). However, immunohistochemical analysis of these enzymes in pheochromocytoma and extra-adrenal




Fig. 5. There are no immunoreactive cells to PNMT in a norepinephrine-producing adrenal pheochromocytoma. $\times 400$. (Case: 51-year-old female; plasma epinephrine: 75 pg/ml; plasma norepinephrine: 4100 pg/ml; tumour size: 55 \times 45 \times 40 mm, 53 g)




Fig. 6. Pheochromocytoma of the urinary bladder, non-functioning, complete type. This tumour is indistinguishable from a functioning pheochromocytoma. H&E, $\times 200$. (Case: 23-year-old male; plasma epinephrine: 16 pg/ml; plasma norepinephrine: 60 pg/ml; tumour size: 75 \times 55 \times 45 mm, 60 g. Tumour metastases to regional lymph nodes were confirmed)

paraganglioma has been very limited (Lloyd et al. 1986; Takahashi et al. 1987; Osamura et al. 1990; Schröder et al. 1990; Kimura 1991; Kimura et al. 1991).

We divided non-functioning pheochromocytomas into two groups: complete and incomplete types. The former was defined as a tumour with no evidence of catecholamine production which was determined by analysis of both plasma catecholamines and their metabolites in urine. The latter was defined as a tumour with a normal level of plasma catecholamine and no clinical symptoms associated with hypercatecholaminaemia, but with a slightly increased urinary VMA. Some stimulation such as intra-operative palpation may induce catecholamine release into the blood and hypertension. In

the unknown group, which had not been examined by catecholamine analysis pre-operatively, all 5 extra-adrenal cases had neither hypertension nor other symptoms associated with hypercatecholaminaemia. These cases may be included with the non-functioning tumours of the complete or incomplete type.

There were no cells immunoreactive to TH in a non-functioning pheochromocytoma, a complete tumour of the urinary bladder, 2 carotid body tumours and a spinal cord tumour of the unknown group. TH-negative tumours were larger than the positive, with a mean size of 3.0 cm versus 0.5 cm in maximum diameter. However, three non-functioning incomplete type pheochromocytomas of the adrenal gland had many cells positive for




Fig. 7. There are no cells immunoreactive to TH in non-functioning phaeochromocytoma, complete type (same case as Fig. 6, $\times 400$)




Fig. 8. Even in TH-negative case, AADC immunoreactivity is observed in non-functioning tumour (same case as Fig. 7, $\times 400$)

TH. Non-functioning complete-type phaeochromocytomas had no or very few cells immunoreactive to TH but the incomplete type had no abnormal expression of TH immunoreactivity. The TH-negative cases were all extra-adrenal.

TH is the rate-limiting enzyme of catecholamine biosynthesis and if it is deficient or small in amount, the tumour might be unable to produce excessive catecholamines despite the presence of enzymes such as AADC, DBH and PNMT. Thus, we believe that TH deficiency is a characteristic feature of the non-functioning, complete-type tumours, which were all extra-adrenal tumours. Osamura et al. (1990) reported that 3 of 4 cases with a low level of plasma catecholamines (non-func-

tioning cases) showed equivocal staining for TH and the remaining case was weakly positive, although TH immunoreactivity was strongly positive in tumours producing high catecholamine levels. Furthermore, 2 extra-adrenal malignant phaeochromocytomas were negative for TH (Osamura et al. 1990). Schröder et al. (1990) also reported that positivity for TH in the adrenal phaeochromocytomas was strictly correlated with the presence of endocrine symptoms. In the cases of the craniocervical region (Takahashi et al. 1987), all 3 tumours examined were positive for TH, but 2 of the above 3 cases had no immunoreactive cells for TH in metastatic sites in cervical lymph nodes. Takahashi et al. (1987) have speculated that the TH-negative tumour cells were imma-




Fig. 9. The intensity of immunoreactivity and the number of DBH-positive cells are less than those of functioning phaeochromocytoma (same case as Fig. 8, $\times 400$)

ture in nature and tended to show malignant behaviour. However, in the present study, all functioning tumours, including malignant cases with multiple distant metastases, showed strong immunoreactivity to TH even at the metastatic sites. Thus, deficiency of TH immunoreactivity itself is not reliable evidence of malignancy, but it may be an expression of cell immaturity and may correlate with malignant transformation.

Despite considerable research in this field, a definition of malignancy in phaeochromocytomas is still controversial. Distant metastasis seems to be the only acceptable criterion for malignancy. We have investigated 38 benign and 26 malignant phaeochromocytomas which had distant multiple metastases (Kimura and Sasano 1990) and reported that malignant phaeochromocytomas could be classified into four types: spindle-shaped cell type, small round cell type, pseudo-rosette-forming type and mixed neuroendocrine-neural type. Malignant tumours were shown to be composed of significantly smaller cells with a higher nuclear/cytoplasmic ratio when compared into that of benign tumours. Nuclear DNA measurement also revealed a high mode with a peak at 3C and narrow variance in malignant tumours, and a low mode with wide variance in benign tumours. Immunohistochemical studies of intermediate filaments, peptide hormones, S100 protein etc. have not contributed to the definition of malignancy in phaeochromocytomas (Kimura and Sasano 1990; Schröder et al. 1990).

AADC is an essential enzyme for the formation of both serotonin and catecholamine and widespread distribution of AADC has been found in most of the neuroendocrine system (Gazdar et al. 1988). An extensive study of AADC in phaeochromocytomas, however, was performed for the first time in the present study. AADC immunoreactivity was observed in all tumours, even in TH-negative non-functioning lesions.

In functioning phaeochromocytomas all three enzymes, TH, AADC and DBH, were present in both nor-

epinephrine-producing and mixed tumours. PNMT, however, was localized only in the cytoplasm of tumour cells of the mixed-type tumours of the adrenal gland and retroperitoneum. There was a close correlation between localization of PNMT and epinephrine production in phaeochromocytoma. Neither norepinephrine-producing nor extra-adrenal non-functioning tumours expressed PNMT.

All tumours of the non-functioning, incomplete type and unknown group in the adrenal medulla had four enzymes and were considered to be mixed phaeochromocytomas. Epinephrine-producing phaeochromocytoma (mixed type) does not necessarily lead to development of hypertension. Why some tumours of the non-functioning, incomplete type having all four enzymes do not secrete excessive norepinephrine or epinephrine into blood remains to be clarified.

In situ hybridization is another powerful approach to the study of regulation of these enzymes (Han et al. 1987; Schalling et al. 1987). Whether TH mRNA is absent or significantly reduced in non-functioning tumours of the complete type should be investigated further.

Acknowledgements. We thank Miss Mika Komori and Miss Aki Tsukano for their secretarial assistance. This study was supported in part by a Grant-in-Aid for Scientific Research, No. 01570170, from the Ministry of Education, Science and Culture, Japan.

References

- Eränkö O, Lempinen M, Räisänen L (1966) Adrenaline and noradrenaline in the organ of Zuckerkindl and adrenals of newborn rats treated with hydrocortisone. *Acta Physiol Scand* 66:253–254
- Gazdar AF, Helman LJ, Israel MA, Russell EK, Linnoila I, Mulshine JL, Schuller HM, Park J-G (1988) Expression of neuroendocrine cell marker L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and neuroendocrine origin. *Cancer Res* 48:4078–4082

- Goldstein M, Fux K, Hokfelt T, Joh TH (1971) Immunohistochemical studies on phenylethanolamine *N*-methyltransferase, dopa decarboxylase and dopamine-hydroxylase. *Experientia* 27:951–952
- Han VKM, Snouweart J, Towle AC, Lund PK, Lauder JM (1987) Cellular localization of tyrosine hydroxylase mRNA and its regulation in the rat adrenal medulla and brain by in situ hybridization with an oligodeoxyribonucleotide probe. *J Neurosci Res* 17:11–18
- Kimura N (1991) Functioning and non-functioning adrenal medullary tumors. *Endocr Pathol* 2:64–73
- Kimura N, Sasano N (1990) A comparative study between malignant and benign pheochromocytoma using morphometry, cytophotometry, and immunohistochemistry. In: Lechago J, Kameya T (eds) *Endocrine pathology update*. Field and Wood, New York, pp 99–118
- Kimura N, Sasano N, Miura Y, Kobayashi K (1984) Adrenal and extra-adrenal pheochromocytomas: an ultrastructural and formaldehyde-induced fluorescence study with catecholamine content. *Tohoku J Exp Med* 142:1–14
- Kimura N, Sasano N, Yamada R, Satoh J (1988) Immunohistochemical study of chromogranin in 100 cases of pheochromocytoma, carotid body tumor, medullary thyroid carcinoma and carcinoid tumor. *Virchows Arch [A]* 413:3–10
- Kimura N, Nakazato Y, Nagura H, Sasano N (1990) Expression of intermediate filaments in neuroendocrine tumors. *Arch Pathol Lab Med* 114:506–510
- Kimura N, Miura Y, Miura K, Takahashi N, Osamura RY, Nagatsu I, Nagura H (1991) Adrenal and retroperitoneal mixed neuroendocrine and neural tumours. *Endocr Pathol* 2:139–147
- Lloyd RV, Sisson JC, Shapiro B, Verhoffsad AAJ (1986) Immunohistochemical localization of epinephrine, norepinephrine, catecholamine-synthesizing enzymes, and chromogranin in neuroendocrine cells and tumors. *Am J Pathol* 125:45–54
- Nagatsu I, Kondo Y (1974) Immunoelectron microscopic localization of phenylethanol-amine-*N*-methyltransferase in the bovine adrenal medulla. *Histochemistry* 42:351–358
- Nagatsu I, Sakai M, Yoshida M, Nagatsu T (1988) Aromatic L-amino acid decarboxylase-immunoreactive neurons in and around the cerebrospinal fluid-contacting neurons of the central canal do not contain dopamine or serotonin in the mouse and rat spinal cord. *Brain Res* 475:91–102
- Osamura RY, Yasuda O, Kawai K, Hori S, Suemizu H, Onoda N, Joh TH (1990) Immunohistochemical localization of catecholamine-synthesizing enzymes in human pheochromocytomas. *Endocr Pathol* 1:102–108
- Schalling M, Dagerlind A, Bren S, Petterson R, Kvist S, Brownstein M, Hyman SE, Mucke L, Goodman HM, Joh TH, Goldstein M, Hokfelt T (1987) Localization of mRNA for phenylethanolamine *N*-methyltransferase (PNMT) using in situ hybridization. *Acta Physiol Scand* 131:531–632
- Schröder S, Padberg B, Achilles E, Grabe E, Dralle H, Klöpfer G (1990) Immunocytochemical and DNA cytophotometrical findings in adrenal pheochromocytoma (PCC). *Acta Endocrinol (Copenh)* 122 [Suppl 1]:1
- Takahashi H, Nakashima S, Kumanishi T, Ikuta F (1987) Paragangliomas of the craniocervical region. An immunohistochemical study on tyrosine hydroxylase. *Acta Neuropathol (Berl)* 73:227–232
- Verhofstad AAJ, Häkfelt T, Goldstein M, Steinbusch HWM, Joosten HWJ (1979) Appearance of tyrosine hydroxylase, aromatic amino-acid decarboxylase, dopamine- β -hydroxylase and phenylethanolamine *N*-methyltransferase during the ontogenesis of the adrenal medulla. *Cell Tissue Res* 200:1–13
- Verhofstad AAJ, Steinbusch HWM, Joosten HWJ, Penke B, Varga J, Goldstein M (1983) Immunocytochemical localization of noradrenalin, adrenalin and serotonin. In: Polak JM, Van Noorden S (eds) *Immunocytochemistry: practical applications in pathology and biology*. Wright PSG, Bristol, pp 143–168
- Wurtman RJ, Axelrod J (1966) Control of enzymatic synthesis of adrenalin in the adrenal medulla by adrenal cortical steroids. *J Biol Chem* 241:2301–2308